Cargando…
An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553947/ https://www.ncbi.nlm.nih.gov/pubmed/28800598 http://dx.doi.org/10.1371/journal.pone.0182815 |
_version_ | 1783256703934922752 |
---|---|
author | Blanco, Natalia Foxman, Betsy Malani, Anurag N. Zhang, Min Walk, Seth Rickard, Alexander H. Eisenberg, Marisa C. |
author_facet | Blanco, Natalia Foxman, Betsy Malani, Anurag N. Zhang, Min Walk, Seth Rickard, Alexander H. Eisenberg, Marisa C. |
author_sort | Blanco, Natalia |
collection | PubMed |
description | BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence and effectiveness of treatment of recurring CDI remains unclear. We aim to assess the role of sporulation/germination patterns on risk of recurrence, and the relative effectiveness of the recommended tapered/pulsing regimens using an in silico model. METHODS: We created a compartmental in-host mathematical model of CDI, composed of vegetative cells, toxins, and spores, to explore whether sporulation and germination have an impact on recurrence rates. We also simulated the effectiveness of three tapered/pulsed vancomycin regimens by ribotype. RESULTS: Simulations underscored the importance of sporulation/germination patterns in determining pathogenicity and transmission. All recommended regimens for recurring CDI tested were effective in reducing risk of an additional recurrence. Most modified regimens were still effective even after reducing the duration or dosage of vancomycin. However, the effectiveness of treatment varied by ribotype. CONCLUSION: Current CDI vancomycin regimen for treating recurrent cases should be studied further to better balance associated risks and benefits. |
format | Online Article Text |
id | pubmed-5553947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55539472017-08-25 An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection Blanco, Natalia Foxman, Betsy Malani, Anurag N. Zhang, Min Walk, Seth Rickard, Alexander H. Eisenberg, Marisa C. PLoS One Research Article BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence and effectiveness of treatment of recurring CDI remains unclear. We aim to assess the role of sporulation/germination patterns on risk of recurrence, and the relative effectiveness of the recommended tapered/pulsing regimens using an in silico model. METHODS: We created a compartmental in-host mathematical model of CDI, composed of vegetative cells, toxins, and spores, to explore whether sporulation and germination have an impact on recurrence rates. We also simulated the effectiveness of three tapered/pulsed vancomycin regimens by ribotype. RESULTS: Simulations underscored the importance of sporulation/germination patterns in determining pathogenicity and transmission. All recommended regimens for recurring CDI tested were effective in reducing risk of an additional recurrence. Most modified regimens were still effective even after reducing the duration or dosage of vancomycin. However, the effectiveness of treatment varied by ribotype. CONCLUSION: Current CDI vancomycin regimen for treating recurrent cases should be studied further to better balance associated risks and benefits. Public Library of Science 2017-08-11 /pmc/articles/PMC5553947/ /pubmed/28800598 http://dx.doi.org/10.1371/journal.pone.0182815 Text en © 2017 Blanco et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Blanco, Natalia Foxman, Betsy Malani, Anurag N. Zhang, Min Walk, Seth Rickard, Alexander H. Eisenberg, Marisa C. An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title | An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title_full | An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title_fullStr | An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title_full_unstemmed | An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title_short | An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection |
title_sort | in silico evaluation of treatment regimens for recurrent clostridium difficile infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553947/ https://www.ncbi.nlm.nih.gov/pubmed/28800598 http://dx.doi.org/10.1371/journal.pone.0182815 |
work_keys_str_mv | AT blanconatalia aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT foxmanbetsy aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT malanianuragn aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT zhangmin aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT walkseth aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT rickardalexanderh aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT eisenbergmarisac aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT blanconatalia insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT foxmanbetsy insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT malanianuragn insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT zhangmin insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT walkseth insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT rickardalexanderh insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection AT eisenbergmarisac insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection |